EN / CN
Contact Us

TNF is a pleiotropic cytokine that acts on a wide variety of cell types. It is predominantly secreted by macrophages, but can also be produced by other immune and nonimmune cells including fibroblasts, muscle cells and endothelial cells. It affects nearly all cell types and plays a critical role in immune function, inflammation, as well as the regulation of cell growth, differentiation and apoptosis.

TNF is a homotrimeric protein that exists in two forms: a transmembrane form and a soluble form (mTNF and sTNF).

Transmembrane TNFα (tmTNFα) is the initially synthesized precursor form, which is cleaved by TNFα converting enzyme (TACE) to release soluble TNFα (sTNFα). In general, TNFα binds to its receptors, mainly TNFR1 and TNFR2, and then transmits molecular signals to mediate biological functions such as inflammation and cell death.


1. TNFα Signaling Pathway


Upon activation by sTNFα and tmTNFα, TNFR1 triggers the assembly of distinct signaling complexes termed Complex I, IIa, IIb and IIc, which drive divergent cellular responses. During Complex I assembly, activated TNFR1 associates with TRADD, followed by the recruitment and interaction of multiple components including RIPK1 (receptorinteracting serine/threonineprotein kinase 1), TRAF2/5 (TNFRassociated factor 2 or 5), cIAP1/2 (cellular inhibitor of apoptosis protein 1 or 2), and LUBAC (linear ubiquitin chain assembly complex). This signaling cascade activates NFκB and MAPK (mitogenactivated protein kinase), inducing inflammation, tissue degeneration, cell survival and proliferation, as well as immune defense against pathogens. Complex IIa and IIb activate caspase8 to induce apoptosis; Complex IIc triggers phosphorylation of MLKL (mixed lineage kinase domainlike protein) via RIPK3, thereby mediating necroptosis and inflammation.

Because TNFR2 lacks an intracellular death domain, it does not directly trigger programmed cell death. TRAF proteins through its TRAFbinding domain to promote Complex I formation, leading to the activation of NFκB, MAPKs and AKT. TNFR2 activation is linked to homeostatic bioactivities such as tissue regeneration, cell proliferation and survival, host defense and inflammation.

TNFα signaling pathway diagram, doi: 10.3390/ijms22052719


2. Roles of TNFα in Related Diseases


2.1 Oral Squamous Cell Carcinoma

TNF-α may serve as a potential biomarker and therapeutic target in OSCC. Elevated TNFα within the tumor microenvironment promotes invasiveness by conferring a proinflammatory and proinvasive phenotype on OSCC cells and mediating the recruitment and activation of inflammatory cells via paracrine mechanisms. Functions of TNFα in OSCC: (1) Stimulation of the NFκB signaling pathway by TNFα promotes stromal invasion of OSCC; (2) TNFα activates Snail (zincfinger transcription factor), a transcriptional repressor that downregulates Ecadherin, and triggers the epithelialmesenchymal transition (EMT) machinery, which enables invasion and migration of oral squamous carcinoma cells.

Diagram illustrating the roles of TNFα in the initiation and progression of OSCC, doi: 10.3390/cancers15061841

TNF-α levels may also serve as potential biomarkers in liquid biopsies for OSCC and its premalignant lesions and disorders, as shown in the table below.

Table source: doi: 10.3390/cancers15061841

2.2 Neuropathic Pain

TNFα induces and modulates neuropathic pain by facilitating peripheral (primary afferent) and central (spinal) sensitization. TNFα modulates voltagegated sodium channels in the peripheral nervous system to sensitize primary afferents, modulates excitatory and inhibitory synaptic transmission in the central nervous system, and forms a positive feedback loop between TNFα and microglial activation to provoke neuroinflammation, thereby facilitating pain transmission, painrelated adverse emotional responses and cognitive deficits. TNFαtriggered necroptosis in the dorsal root ganglia, spinal cord and supraspinal regions may be one of the key factors driving neuroimmune responses in neuropathic pain.

Diagram depicting potential mechanisms of peripheral and central sensitization via TNFα or the TNFα–necroptosis pathway in neuropathic pain, doi: 10.3390/ijms23137191

2.3 COVID19

TNF-α is a key pro-inflammatory cytokine involved in acute lung injury. It can trigger cytokine release syndrome and promote the interaction between SARSCoV2 and angiotensinconverting enzyme 2 (ACE2). ACE2 shedding induced by the SARSCoV spike protein is strongly associated with TNFα under cell culture conditions. Exaggerated inflammatory responses in severe COVID19 patients correlate with increased TNFα and IL6, possibly driven by NFκB. Respiratory viruses including SARSCoV can also induce hyperactivation of NFκB, resulting in pulmonary inflammatory immunopathology.

Diagram showing the critical role of TNFα in NFκB activation and ACE2 shedding during SARSCoV2 infection, doi: 10.3389/fpubh.2022.833967

2.4 Autoimmune Diseases

TNFα participates in immune regulation; however, aberrant secretion of TNFα can induce autoimmune diseases such as rheumatoid arthritis (RA), inflammatory bowel disease (IBD), psoriatic arthritis (PsA), psoriasis (PS) and noninfectious uveitis (NIU).

2.4.1 Rheumatoid Arthritis

TNFα is recognized as a major proinflammatory cytokine involved in the pathogenesis of RA and is highly expressed in patients with this disease. In RA, TNFα secreted by Th1 cells and macrophages activates synovial fibroblasts, promotes synovial hyperplasia and recruits inflammatory cells. Upon activation by multiple cytokines including IL1, IL6 and TNFα, synovial fibroblasts overexpress cathepsins and matrix metalloproteinases (MMPs), which subsequently degrade collagens and proteoglycans. Consequently, cartilage and bone are destroyed, ultimately leading to joint erosion. TNFα also activates osteoclasts together with synovial fibroblasts to drive joint damage.

2.4.2 Psoriatic Arthritis

In PsA, TNFαactivated dendritic cells (DCs) and macrophages overproduce TNFα and IL23. IL23 drives the differentiation of T cells into Th17 cells, which overproduce IL17. IL17 and TNFα then activate keratinocytes, promote epidermal hyperplasia and recruit inflammatory cells such as DCs. TNFα induces keratinocyte proliferation and apoptosis resistance via the NFκB signaling pathway, and eventually leads to microabscess formation by enhancing the recruitment of inflammatory cells in psoriasis.

Diagram illustrating the roles of TNFα in rheumatoid arthritis and psoriatic arthritis

2.4.3 Inflammatory Bowel Disease

Crohn’s disease and ulcerative colitis (UC) are the two major subtypes of IBD, which differ in their anatomical distribution and pathological features. Th1 cells secrete TNFα and other cytokines, which recruit intestinal fibroblasts, neutrophils and macrophages in the gut. Intestinal fibroblasts induce fibrosis and stricture formation. Neutrophils release elastase and other proteases that contribute to extracellular matrix degradation. Macrophages produce additional inflammatory cytokines, resulting in intestinal stromal degradation, epithelial injury, endothelial activation and disruption.

Diagram illustrating the roles of TNFα in inflammatory bowel disease

2.4.4 Psoriasis

TNFα is initially secreted by stressed keratinocytes together with other proinflammatory cytokines. These secreted cytokines activate DCs and induce the differentiation of T cells into Th1 and Th17 cells. Th1 and Th17 cells secrete TNFα, IFNγ and IL17 respectively, causing excessive keratinocyte proliferation and epidermal alterations such as acanthosis, parakeratosis and granulocyte loss.

Diagram illustrating the roles of TNFα in psoriasis

2.4.5 NonInfectious Uveitis

Non-infectious uveitis (NIU) is a group of intraocular inflammatory disorders that can involve the uvea and adjacent ocular tissues. Macrophages secrete TNFα and other cytokines to activate DCs. Activated DCs secrete IL12, IL6 and TGFβ, which drive the differentiation of naïve T cells into Th1 and Th17 cells. Th1 and Th17 cells migrate and infiltrate the uvea, the vascular middle layer of the eye that supplies blood to the retina. Th1 and Th17 cells damage the bloodretinal barrier, trigger retinal vasculopathy and recruit nonspecific circulating leukocytes, ultimately causing uveal swelling and destructive inflammation in NIU.

Diagram illustrating the roles of TNFα in uveitis


3. TNFα Inhibitors


To date, five antiTNFα agents have been approved: infliximab (Remicade®, chimeric humanmouse IgG1 monoclonal antibody against TNF), etanercept (Enbrel®, fusion protein), adalimumab (Humira®, fully human antiTNFα antibody), golimumab (Simponi®, fully human antiTNFα IgG1κ monoclonal antibody) and certolizumab pegol (Cimzia®, pegylated Fab fragment of a humanized antiTNFα antibody).

Numerous clinical trials are ongoing to evaluate the therapeutic efficacy of TNFα inhibitors in a broad spectrum of diseases. Notably, phase 2–3 trials are investigating TNFα inhibitors in patients with vasculitides including Behçet’s disease, Takayasu arteritis, granulomatosis with polyangiitis and pemphigus vulgaris, as well as for graftversushost disease prophylaxis.

Ongoing clinical studies on future applications of TNFα inhibitors registered on clinicaltrials.gov

QYAOBIO (ChinaPeptides Co., Ltd.) has focused on peptide synthesis, protein expression and antibody preparation for 15 years. We provide human and murine TNFα as well as other recombinant protein products. Please feel free to contact us if you have any requirements!


References


[1] Jang D I, Lee A H, Shin H Y, et al. The Role of Tumor Necrosis Factor Alpha (TNFα) in Autoimmune Disease and Current TNFα Inhibitors in Therapeutics. International Journal of Molecular Sciences, 2021, 22(5): 2719. doi: 10.3390/ijms22052719.

[2] Brierly G, Celentano A, Breik O, et al. Tumour Necrosis Factor Alpha (TNFα) and Oral Squamous Cell Carcinoma. Cancers, 2023, 15(6): 1841. doi: 10.3390/cancers15061841.

[3] Duan Y W, Chen S X, Li Q Y, et al. Neuroimmune Mechanisms Underlying Neuropathic Pain: The Potential Role of TNFαNecroptosis Pathway. International Journal of Molecular Sciences, 2022, 23(13): 7191. doi: 10.3390/ijms23137191.

[4] Guo Y, Hu K, Li Y, et al. Targeting TNFα for COVID19: Recent Advances and Controversies. Frontiers in Public Health, 2022, 10: 833967. doi: 10.3389/fpubh.2022.833967.

[5] Leone G M, Mangano K, Petralia M C, et al. Past, Present and (Foreseeable) Future of Biological AntiTNF Alpha Therapy. Journal of Clinical Medicine, 2023, 12(4), 1630. doi: 10.3390/jcm12041630.


Top